Female Reproductive System Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FML039 MIFTS: 38	Female Reproductive System Disease Categories: Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Female Reproductive System Disease

MalaCards integrated aliases for Female Reproductive System Disease:

Name: Female Reproductive System Disease ¹¹ ¹⁴ ¹⁶

Female Reproductive System Disorder ⁷¹

Genital Diseases, Female ⁴³

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:229

ICD9CM ³⁴ 629.9

MeSH ⁴³ D005831

SNOMED-CT ⁶⁸ 38233001

EFO ¹⁶ EFO_0009549

UMLS ⁷¹ C0017411 C0236100

Sources

Summaries for Female Reproductive System Disease

Disease Ontology: ¹¹ A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary: Female Reproductive System Disease, also known as female reproductive system disorder, is related to uterine anomalies and ovarian disease, and has symptoms including menometrorrhagia, mastodynia and breast engorgement. An important gene associated with Female Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and miRNAs involvement in the immune response in sepsis. The drugs Dydrogesterone and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and breast.

Sources

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)

#	Related Disease	Score	Top Affiliating Genes
1	uterine anomalies	32.8	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
2	ovarian disease	32.8	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
3	endometriosis	32.7	MIR200A MIR199A1 MIR17 MIR145 MIR143 MIR142
4	endometriosis of ovary	32.7	MIR9-1 MIR199A1 MIR145 MIR141 MIR139
5	preterm premature rupture of the membranes	11.2
6	ectopic pregnancy	11.2
7	pelvic inflammatory disease	11.2
8	fallopian tube endometriosis	11.2
9	endosalpingiosis	11.2
10	endometriosis of intestine	11.2
11	endometriosis of pelvic peritoneum	11.2
12	endometriosis in scar of skin	11.2
13	endometriosis of rectovaginal septum and vagina	11.2
14	vaginal disease	11.2
15	hernia of ovary and fallopian tube	11.2
16	prolapse of female genital organ	11.2
17	amenorrhea	11.2
18	masters-allen syndrome	11.2
19	fallopian tube disease	11.2
20	vulvar disease	11.2
21	vulvovaginitis	11.2
22	gynatresia	11.2
23	parovarian cyst	11.2
24	bartholin's gland disease	11.2
25	bartholin's duct cyst	11.2
26	nervous system disease	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
27	reproductive system disease	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
28	bladder disease	10.7	MIR9-1 MIR34A MIR30A MIR214 MIR21 MIR200A
29	gastrointestinal system disease	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
30	gastrointestinal system cancer	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
31	endocrine gland cancer	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
32	respiratory system disease	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
33	hepatocellular carcinoma	10.7	MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
34	lung cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
35	stomach disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
36	connective tissue disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
37	large intestine cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
38	intestinal disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
39	thoracic cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
40	male reproductive organ cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
41	central nervous system cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
42	breast disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
43	immune system disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
44	endocrine system disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
45	pancreas disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
46	cervix disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
47	ovary epithelial cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
48	connective tissue cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
49	lymphatic system disease	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
50	bone cancer	10.7	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21

Graphical network of the top 20 diseases related to Female Reproductive System Disease:

Sources

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:

menometrorrhagia; mastodynia; breast engorgement; nipple discharge; leukorrhea; vaginal pruritus; vaginal odor; vaginal discomfort; pruritus vulvae; genital itching; perineal pain female; genitalia external painful; menopausal symptoms; vaginal pain; burning feeling vagina; mastoscirrhus; discomfort of vulva

Sources

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dydrogesterone

Approved, Investigational, Withdrawn

Phase 4

152-62-5

9051

Progesterone

Approved, Vet_approved

Phase 4

57-83-0

5994

Hormones

Phase 4

Hormone Antagonists

Phase 4

Progestins

Phase 4

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Angiogenesis Inhibitors

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Niraparib

Approved, Investigational

Phase 2

1038915-60-4

24958200

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Olaparib

Approved

Phase 2

763113-22-0

23725625

Pharmaceutical Solutions

Phase 2

Vaccines

Phase 2

Immunologic Factors

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Alkylating Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Antiemetics

Phase 2

glucocorticoids

Phase 2

Anti-Inflammatory Agents

Phase 2

Gastrointestinal Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Infective Agents

Phase 2

Antifungal Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Immunosuppressive Agents

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Lidocaine

Approved, Vet_approved

137-58-6

3676

Ritonavir

Approved, Investigational

155213-67-5

392622

Racivir

Approved, Investigational

143491-57-0, 143491-54-7

60877

Heparin, bovine

Approved, Investigational, Withdrawn

9005-49-6

22833565 9812414 772

Nadroparin

Approved, Investigational

Tenofovir

Experimental, Investigational

147127-20-6, 202138-50-9

464205 6398764

Insulin, Globin Zinc

Insulin

Anti-Arrhythmia Agents

Sodium Channel Blockers

Anesthetics, Local

Anesthetics

Interventional clinical trials:

(show all 23)

#	Name	Status	NCT ID	Phase	Drugs
1	Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the Peripheral Immunology. Double Blind Crossover Study.	Completed	NCT03677336	Phase 4	Dydrogesterone Oral Tablet;Micronized progesterone;Placebo Dydrogesterone oral tablet;Placebo Micronized progesterone
2	Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study	Unknown status	NCT02097446	Phase 3
3	A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	Completed	NCT01462890	Phase 3	Paclitaxel;Carboplatin
4	A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	Unknown status	NCT04556071	Phase 2	Niraparib;Bevacizumab
5	Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.	Completed	NCT03562897	Phase 2
6	A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women	Completed	NCT00365716	Phase 2
7	Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer	Completed	NCT00050414	Phase 2	Trabectedin;Dexamethasone
8	Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma	Completed	NCT01460979	Phase 2	Temsirolimus
9	A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Recruiting	NCT04566952	Phase 2	Anlotinib;Olaparib
10	A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer	Not yet recruiting	NCT04807166	Phase 2	Drug: Anlotinib;Drug: Carboplatin/Paclitaxel
11	Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates	Unknown status	NCT01271400
12	Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers	Completed	NCT02233283
13	Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects	Completed	NCT02747641
14	A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse	Completed	NCT02642835
15	The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies	Completed	NCT02698527		Non-Buffered Lidocaine;Buffered Lidocaine
16	Transrectal Ultrasound and 3D Transabdominal Ultrasound in Comparison to Vaginoscopy in Virgins With Suspected Genital Tract Lesions	Completed	NCT04858919
17	Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial	Completed	NCT01628432
18	Influence of Raltegravir-Containing Antiretroviral Therapy (ART) on Immune Reconstitution and Activation in the Female Genital Tract	Completed	NCT01456962
19	A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy	Completed	NCT01526668
20	Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche	Completed	NCT01523652
21	Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer	Recruiting	NCT04678414
22	Can SMS-reminders Result in Increased Participation in Cervical Screening?	Recruiting	NCT04061967
23	Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)	Not yet recruiting	NCT04746053

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Sources

Genetic Tests for Female Reproductive System Disease

Sources

Anatomical Context for Female Reproductive System Disease

Organs/tissues related to Female Reproductive System Disease:

MalaCards : Cervix, Uterus, Breast

Sources

Publications for Female Reproductive System Disease

Articles related to Female Reproductive System Disease:

#	Title	Authors	PMID	Year
1	Integrated Analysis Identifies Four Genes as Novel Diagnostic Biomarkers Which Correlate with Immune Infiltration in Preeclampsia. ⁶²	Yang MY...Lei L	35528613	2022
2	Evidence-based core information for health communication of tobacco control: The effect of smoking on risks of female disease. ⁶²	Liu J...Wu YB	36330111	2022
3	[Analysis on reproductive health status and influencing factors of female workers of pharmaceutical industry in Gansu province]. ⁶²	Kou ZX...Zhou AS	22356709	2011

Sources

Genes for Female Reproductive System Disease

Genes related to Female Reproductive System Disease (0 elite genes):

(show top 50) (show all 119)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR199A1	MicroRNA 199a-1	RNA Gene	17.4	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
2	MIR518D	MicroRNA 518d	RNA Gene	14.61	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
3	MIR21	MicroRNA 21	RNA Gene	13.43	DISEASES inferred ¹⁴ ¹⁴
4	MIR518A1	MicroRNA 518a-1	RNA Gene	12.8	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
5	H2AC18	H2A Clustered Histone 18	Protein Coding	12.52	DISEASES inferred ¹⁴ ¹⁴
6	MIR141	MicroRNA 141	RNA Gene	12.36	DISEASES inferred ¹⁴ ¹⁴
7	MIR145	MicroRNA 145	RNA Gene	12.31	DISEASES inferred ¹⁴ ¹⁴
8	MIR17	MicroRNA 17	RNA Gene	12.28	DISEASES inferred ¹⁴ ¹⁴
9	MIR200A	MicroRNA 200a	RNA Gene	11.95	DISEASES inferred ¹⁴ ¹⁴
10	MIR214	MicroRNA 214	RNA Gene	11.92	DISEASES inferred ¹⁴ ¹⁴
11	MIR143	MicroRNA 143	RNA Gene	11.86	DISEASES inferred ¹⁴ ¹⁴
12	MIR9-1	MicroRNA 9-1	RNA Gene	11.84	DISEASES inferred ¹⁴ ¹⁴
13	MIR139	MicroRNA 139	RNA Gene	11.78	DISEASES inferred ¹⁴ ¹⁴
14	MIR30A	MicroRNA 30a	RNA Gene	11.75	DISEASES inferred ¹⁴ ¹⁴
15	MIR196A1	MicroRNA 196a-1	RNA Gene	11.74	DISEASES inferred ¹⁴ ¹⁴
16	MIR193A	MicroRNA 193a	RNA Gene	11.72	DISEASES inferred ¹⁴ ¹⁴
17	MIR142	MicroRNA 142	RNA Gene	11.68	DISEASES inferred ¹⁴ ¹⁴
18	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	11.58	DISEASES inferred ¹⁴ ¹⁴
19	MIR34A	MicroRNA 34a	RNA Gene	11.57	DISEASES inferred ¹⁴ ¹⁴
20	MIR126	MicroRNA 126	RNA Gene	11.57	DISEASES inferred ¹⁴ ¹⁴
21	MIR27A	MicroRNA 27a	RNA Gene	11.5	DISEASES inferred ¹⁴ ¹⁴
22	MIR125A	MicroRNA 125a	RNA Gene	11.44	DISEASES inferred ¹⁴ ¹⁴
23	MIR140	MicroRNA 140	RNA Gene	11.41	DISEASES inferred ¹⁴ ¹⁴
24	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	11.28	DISEASES inferred ¹⁴ ¹⁴
25	MIR200B	MicroRNA 200b	RNA Gene	11.26	DISEASES inferred ¹⁴ ¹⁴
26	MIR205	MicroRNA 205	RNA Gene	11.21	DISEASES inferred ¹⁴ ¹⁴
27	MIR221	MicroRNA 221	RNA Gene	11.21	DISEASES inferred ¹⁴ ¹⁴
28	MIR223	MicroRNA 223	RNA Gene	11.18	DISEASES inferred ¹⁴ ¹⁴
29	MIR146A	MicroRNA 146a	RNA Gene	11.17	DISEASES inferred ¹⁴ ¹⁴
30	MIR31	MicroRNA 31	RNA Gene	11.17	DISEASES inferred ¹⁴ ¹⁴
31	MIR93	MicroRNA 93	RNA Gene	11.13	DISEASES inferred ¹⁴ ¹⁴
32	MIR424	MicroRNA 424	RNA Gene	11.13	DISEASES inferred ¹⁴ ¹⁴
33	MIR204	MicroRNA 204	RNA Gene	11.09	DISEASES inferred ¹⁴ ¹⁴
34	MIR361	MicroRNA 361	RNA Gene	11.08	DISEASES inferred ¹⁴ ¹⁴
35	MIR155	MicroRNA 155	RNA Gene	11.04	DISEASES inferred ¹⁴ ¹⁴
36	MIR149	MicroRNA 149	RNA Gene	11.03	DISEASES inferred ¹⁴ ¹⁴
37	MIR200C	MicroRNA 200c	RNA Gene	11.02	DISEASES inferred ¹⁴ ¹⁴
38	MIR144	MicroRNA 144	RNA Gene	11.02	DISEASES inferred ¹⁴ ¹⁴
39	MIR423	MicroRNA 423	RNA Gene	10.98	DISEASES inferred ¹⁴ ¹⁴
40	MIRLET7D	MicroRNA Let-7d	RNA Gene	10.98	DISEASES inferred ¹⁴ ¹⁴
41	MIR101-1	MicroRNA 101-1	RNA Gene	10.93	DISEASES inferred ¹⁴ ¹⁴
42	MIR182	MicroRNA 182	RNA Gene	10.93	DISEASES inferred ¹⁴ ¹⁴
43	MIR15A	MicroRNA 15a	RNA Gene	10.86	DISEASES inferred ¹⁴ ¹⁴
44	MIR486-1	MicroRNA 486-1	RNA Gene	10.83	DISEASES inferred ¹⁴ ¹⁴
45	MIR224	MicroRNA 224	RNA Gene	10.82	DISEASES inferred ¹⁴ ¹⁴
46	MIR34C	MicroRNA 34c	RNA Gene	10.79	DISEASES inferred ¹⁴ ¹⁴
47	MIR22	MicroRNA 22	RNA Gene	10.78	DISEASES inferred ¹⁴ ¹⁴
48	MIR125B1	MicroRNA 125b-1	RNA Gene	10.77	DISEASES inferred ¹⁴ ¹⁴
49	MIR150	MicroRNA 150	RNA Gene	10.75	DISEASES inferred ¹⁴ ¹⁴
50	MIR590	MicroRNA 590	RNA Gene	10.74	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Female Reproductive System Disease

Sources

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Sources

Pathways for Female Reproductive System Disease

Pathways related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	11.28	MIR21 MIR17 MIR145 MIR143
2	miRNAs involvement in the immune response in sepsis ⁷⁴	11.15	MIR9-1 MIR21 MIR199A1 MIR145 MIR126
3	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.11	MIR34A MIR214 MIR21
4	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11	MIR9-1 MIR214 MIR199A1 MIR17 MIR145 MIR143
5	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.58	MIR21 MIR200A

Sources

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.77	MIR9-1 MIR30A MIR214 MIR21 MIR200A MIR199A1
2	extracellular vesicle	GO:1903561	9.5	MIR34A MIR30A MIR214 MIR21 MIR193A MIR17

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 29)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10	MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR17
2	cellular response to hypoxia	GO:0071456	9.91	MIR34A MIR214 MIR17 MIR126
3	positive regulation of angiogenesis	GO:0045766	9.91	MIR30A MIR21 MIR199A1 MIR143 MIR126
4	positive regulation of protein kinase B signaling	GO:0051897	9.9	MIR21 MIR199A1 MIR143 MIR126
5	miRNA-mediated gene silencing	GO:0035195	9.84	MIR126 MIR139 MIR141 MIR142 MIR143 MIR145
6	negative regulation of inflammatory response	GO:0050728	9.83	MIR126 MIR141 MIR142 MIR145 MIR199A1
7	negative regulation of osteoblast differentiation	GO:0045668	9.81	MIR9-1 MIR214 MIR17
8	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.81	MIR214 MIR21 MIR17
9	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.76	MIR199A1 MIR196A1 MIR193A
10	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.75	MIR145 MIR199A1 MIR21
11	negative regulation of cell migration	GO:0030336	9.73	MIR9-1 MIR34A MIR214 MIR21 MIR145 MIR126
12	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.71	MIR34A MIR214 MIR21
13	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.71	MIR30A MIR200A MIR143 MIR126
14	negative regulation of vascular endothelial cell proliferation	GO:1905563	9.67	MIR34A MIR193A MIR126
15	negative regulation of vascular endothelial growth factor production	GO:1904046	9.65	MIR34A MIR199A1 MIR17
16	angiotensin-activated signaling pathway	GO:0038166	9.64	MIR145 MIR143
17	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.63	MIR21 MIR17
18	aorta smooth muscle tissue morphogenesis	GO:0060414	9.62	MIR145 MIR143
19	negative regulation of lamellipodium assembly	GO:0010593	9.62	MIR214 MIR196A1
20	positive regulation of metalloendopeptidase activity	GO:1904685	9.61	MIR21 MIR17
21	negative regulation of BMP secretion	GO:2001285	9.59	MIR214 MIR17
22	regulation of phenotypic switching	GO:1900239	9.57	MIR145 MIR143
23	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.56	MIR17 MIR143
24	positive regulation of cellular response to hypoxia	GO:1900039	9.55	MIR21 MIR145
25	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.55	MIR126 MIR145 MIR17 MIR21 MIR9-1
26	positive regulation of connective tissue replacement	GO:1905205	9.54	MIR34A MIR214 MIR199A1
27	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.5	MIR214 MIR199A1 MIR17
28	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.46	MIR145 MIR143
29	negative regulation of angiogenesis	GO:0016525	9.43	MIR34A MIR214 MIR21 MIR193A MIR145 MIR143

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.8	MIR9-1 MIR34A MIR30A MIR214 MIR21 MIR199A1
2	mRNA base-pairing translational repressor activity	GO:1903231	9.55	MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21